Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.3%) at 17,793 as of Monday, June 8, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,037 issues advancing vs. 1,919 declining with 182 unchanged. The Drugs industry currently sits up 0.8% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include China Biologic Products ( CBPO), down 8.2%, Incyte ( INCY), down 2.2%, Novo Nordisk A/S ( NVO), down 1.6% and AstraZeneca ( AZN), down 0.7%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Eli Lilly and ( LLY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Eli Lilly and is up $0.63 (0.8%) to $78.75 on average volume. Thus far, 1.8 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $77.83-$78.85 after having opened the day at $77.98 as compared to the previous trading day's close of $78.12. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. Eli Lilly and has a market cap of $86.2 billion and is part of the health care sector. Shares are up 13.2% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.